During Thursday’s Current trade, Shares of Incyte Corporation (NASDAQ:INCY), gain 3.58% to $112.37.
Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company focused on the discovery, development and commercialization of innovative proprietary therapeutics, recently declared it has been ranked 7th on Forbes magazine’s 2015 list of the World’s Most Innovative Companies.
Forbes’ ranking is based on the companies’ “innovation premium”, and only comprises industries that are known to invest in innovation and businesses that have at least seven years of financial data and a market value greater than $10 billion.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line comprises ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, in addition to INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer.
Shares of Air Products & Chemicals, Inc. (NYSE:APD), inclined 1.35% to $139.48, during its current trading session.
Air Products (APD), a global leader in helium production, recently held a grand opening at its new Doe Canyon helium production facility in Colorado. The Doe Canyon helium plant is the only one in the world extracting helium from a gas stream composed primarily of carbon dioxide (CO2). The helium from this new facility further diversifies Air Products’ supply chain to ensure a reliable and stable supply of product for its customers.
Much of the helium produced in the United States recently comes from the United States Bureau of Land Administration (BLM) system, however, the BLM system is in decline, and eventually that storage supply will be depleted. At the same time, the world’s demand for helium is likely to continue to grow and is why new sources of helium are needed. The purified helium at the new Colorado facility will be liquefied on-site for subsequent delivery to Air Products’ customers. The plant is predictable to produce up to 230 million standard cubic feet of helium per year, replacing more than 15 percent of the current BLM reserve helium supply as that system declines.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates in Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy segments. The Merchant Gases segment sells atmospheric gases, such as oxygen, nitrogen, and argon; process gases, such as hydrogen, helium, and carbon dioxide; specialty gases; temporary gas supply services; and equipment for the metals, glass, electronics, chemical processing, food processing, healthcare, general manufacturing, and petroleum and natural gas industries.
Peregrine Pharmaceuticals (NASDAQ:PPHM), during its Thursday’s current trading session gained 0.88% to $1.15.
Peregrine Pharmaceuticals, Inc. (PPHM) a biopharmaceutical company focused on developing novel investigational products that assist harness the body’s own immune system to fight cancer, declared financial results for the fourth quarter and the fiscal year (FY) 2015 ended April 30, 2015 and offered an update on its advancing clinical pipeline and other corporate developments.
Highlights Since January 31, 2015:
“During the fourth quarter, Peregrine achieved multiple milestones spanning all areas of the business. Most importantly, we remain on plan to complete patient enrollment in the SUNRISE Phase III trial in NSCLC by the end of calendar year 2015, while also planning for the initiation of two new trials designed to further expand our breast and non-small cell lung cancer clinical programs,” said Steven W. King, president and chief executive officer of Peregrine. “Our promising new partnership with Memorial Sloan Kettering Cancer Center, together with the considerable amount of pre-clinical and clinical data that has been generated, serves to further validate bavituximab and its potential to enhance the effects of chemotherapy, in addition to immune checkpoint targeting treatments. Recently, we are more confident than ever in bavituximab and we are plannedally expanding our clinical programs to capture the value that we believe exists in new therapeutic combinations and indications. Specifically, we are expanding our NSCLC clinical program to comprise a planned Phase II study combining bavituximab with Opdivo®, an FDA-approved PD-1 inhibitor, while also initiating a planned Phase II/III clinical trial in breast cancer combining bavituximab with chemotherapy. In addition to our drug development efforts, Avid achieved record revenue during this fiscal year 2015 and is on track to grow its revenue in FY 2016 based on the growing backlog of services and the near-term launch of the new manufacturing facility. We look forward to providing updates on our bavituximab clinical program, data from presently enrolling clinical trials and collaborative development efforts in the coming months.”
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Finally, Old Republic International Corporation (NYSE:ORI), gained 0.71%, to $15.59.
Old Republic International Corporation (ORI) stated that net operating income for this year’s second quarter and first half exceeded our expectations. The results were bolstered by much improved underwriting performance in the Company’s general insurance business and by continued strength of its title insurance operations. The RFIG run-off segment also posted better year-over-year results partly due to less burdensome litigation claim expense provisions than practiced in the same periods of 2014. This year’s merged net income was comparatively lower as the unusually high level of realized investment gains recognized in the first half of 2014 were not repeated in this year’s second quarter and year-to-date periods.
The preceding table shows both operating and net income to highlight the effects of realized investment gain or loss recognition on period-to-period earnings comparisons. Administration uses net operating income, a non-GAAP financial measure, to evaluate and better explain operating performance, believing that this measure enhances an understanding of Old Republic’s core business results. Operating income, however, does not replace net income determined in accordance with GAAP as a measure of total profitability.
Old Republic International Corporation, through its auxiliaries, engages in the insurance underwriting and related services business primarily in the United States and Canada. The company’s General Insurance Group segment offers automobile extended warranty, aviation, commercial automobile, commercial multi-peril, general liability, home warranty, inland marine, travel accident, and workers’ compensation insurance products; and financial indemnity products for specialty coverages, counting errors and omissions, directors and officers, fidelity, guaranteed asset protection, and surety.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
